- Home
- Publications
- Publication Search
- Publication Details
Title
Nintedanib: First Global Approval
Authors
Keywords
Renal Cell Carcinoma, Docetaxel, Endometrial Cancer, Sunitinib, Idiopathic Pulmonary Fibrosis
Journal
DRUGS
Volume 75, Issue 1, Pages 129-139
Publisher
Springer Nature
Online
2014-12-02
DOI
10.1007/s40265-014-0335-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer
- (2015) Isamu Okamoto et al. Journal of Thoracic Oncology
- Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.
- (2015) Paul Mésange et al. Oncotarget
- Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel
- (2014) Jean-Pierre Droz et al. ANTI-CANCER DRUGS
- Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis
- (2014) Klaus Mross et al. BMC CANCER
- Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)
- (2014) M Quintela-Fandino et al. BRITISH JOURNAL OF CANCER
- Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
- (2014) L Rhoda Molife et al. Future Oncology
- A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
- (2014) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
- (2013) Tim Eisen et al. INVESTIGATIONAL NEW DRUGS
- BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
- (2013) B. Kutluk Cenik et al. MOLECULAR CANCER THERAPEUTICS
- Abstract 3701: Phase II study of BIBF1120 in recurrent glioblastoma multiforme
- (2012) Ulrik Lassen et al. CANCER RESEARCH
- Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
- (2012) Aida Muhic et al. JOURNAL OF NEURO-ONCOLOGY
- A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
- (2011) M. Reck et al. ANNALS OF ONCOLOGY
- Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
- (2011) G Bousquet et al. BRITISH JOURNAL OF CANCER
- Novel therapeutic approaches for pulmonary fibrosis
- (2011) Arnab Datta et al. BRITISH JOURNAL OF PHARMACOLOGY
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Idiopathic pulmonary fibrosis
- (2011) Talmadge E King et al. LANCET
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
- (2010) P. M. Ellis et al. CLINICAL CANCER RESEARCH
- A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
- (2009) A. du Bois et al. ANNALS OF ONCOLOGY
- Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
- (2009) K. Mross et al. CLINICAL CANCER RESEARCH
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started